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Background: Next-generation sequencing (NGS) offers unprecedented opportunities to expand clinical genomics.
It also presents challenges with respect to integration with data from other sequencing methods and historical
data. Provision of consistent, clinically applicable variant annotation of NGS data has proved difficult, particularly
of indels, an important variant class in clinical genomics. Annotation in relation to a reference genome sequence,
the DNA strand of coding transcripts and potential alternative variant representations has not been well addressed.
Here we present tools that address these challenges to provide rapid, standardized, clinically appropriate
annotation of NGS data in line with existing clinical standards.
Methods: We developed a clinical sequencing nomenclature (CSN), a fixed variant annotation consistent with the
principles of the Human Genome Variation Society (HGVS) guidelines, optimized for automated variant annotation
of NGS data. To deliver high-throughput CSN annotation we created CAVA (Clinical Annotation of VAriants), a fast,
lightweight tool designed for easy incorporation into NGS pipelines. CAVA allows transcript specification, appropriately
accommodates the strand of a gene transcript and flags variants with alternative annotations to facilitate clinical
interpretation and comparison with other datasets. We evaluated CAVA in exome data and a clinical BRCA1/BRCA2
gene testing pipeline.
Results: CAVA generated CSN calls for 10,313,034 variants in the ExAC database in 13.44 hours, and annotated
the ICR1000 exome series in 6.5 hours. Evaluation of 731 different indels from a single individual revealed 92 %
had alternative representations in left aligned and right aligned data. Annotation of left aligned data, as performed by
many annotation tools, would thus give clinically discrepant annotation for the 339 (46 %) indels in genes transcribed
from the forward DNA strand. By contrast, CAVA provides the correct clinical annotation for all indels. CAVA also
flagged the 370 indels with alternative representations of a different functional class, which may profoundly
influence clinical interpretation. CAVA annotation of 50 BRCA1/BRCA2 gene mutations from a clinical pipeline
gave 100 % concordance with Sanger data; only 8/25 BRCA2 mutations were correctly clinically annotated by
other tools.
Conclusions: CAVA is a freely available tool that provides rapid, robust, high-throughput clinical annotation of
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Genetic testing has been an important clinical activity
for over 20 years during which time many different
mutation detection methods have been utilized and
many thousands of clinically relevant variant datasets
have been generated. In recent years next-generation
sequencing (NGS) has been transforming clinical genom-
ics, allowing rapid interrogation of tens of thousands of
genes and the identification of millions of variants [1].
Integration of pre-NGS data (typically, but not exclusively,
from Sanger sequencing) and NGS data are essential for
the correct interpretation and management of variants in
the clinical setting, particularly as most clinical laborator-
ies continue to use non-NGS methods for at least some
tests (e.g., testing for individual mutations).
There are important, underappreciated differences in
the outputs of pre-NGS and NGS gene sequencing
methods which are hindering the required integration
of data and thus the potential of genomics to impact
health. The most pressing issue requiring attention is
the huge variability in descriptive terminology of vari-
ants which is endemic both within and between pre-
NGS and NGS annotation systems. For example,
rs80357713 is the identifier of one of the most well
documented variants in the world, an Ashkenazim
BRCA1 founder mutation. Currently, rs80357713 is as-
sociated with 12 different annotations on dbSNP, none
of which is the standard clinical representation of the
mutation: BRCA1 c.68_69delAG [2, 3].
Clinical annotation of pre-NGS sequence data is gen-
erally in accordance with the Human Genome Variation
Society (HGVS) guidelines [4]. However, these permit
alternative annotations of some variants and hence fos-
ter inconsistency. They also allow terms that are incom-
patible with contemporary large-scale variant databases,
such as an asterisk (which is used as a wildcard term in
many applications) for stop-gain mutations. Although
tools such as Mutalyzer [5] and Counsyl [6] can provide
an HGVS consistent annotation for individual, or small
batches, of variants, they are not designed for easy inte-
gration into NGS pipelines which typically generate
thousands of variants per individual. Currently, there are
no universal annotation standards for describing NGS
data, with different tools using similar, but not identical,
notation systems [7–9]. A fixed, standardized, versioned
nomenclature for clinical sequence data, identical for all
mutation detection platforms and readily interchangeable
with historic data, is of vital importance as the global
community seeks to integrate sequencing data from mul-
tiple sources to enable more accurate interpretation of
genomic information in the clinical setting.
A fundamental difference in pre-NGS and NGS variant
annotation is in the selection of the gene transcript
against which to annotate if a variant is present. For pre-NGS methods a RefSeq transcript is typically used. This
often corresponds to an mRNA sequence, usually from a
single individual, and may have undergone curation to
include the major alleles in a given population [10]. For
NGS data, variant detection is made through compari-
son with the reference human genome sequence, which
was generated from several individuals and generally has
not been altered to reflect the major alleles in a specific
population [11]. This difference can impact variant
calling if the RefSeq transcript differs from the reference
genome sequence. The BRCA2 gene exemplifies this
issue. The RefSeq transcript NM_000059.3, which has
historically been used for pre-NGS BRCA2 clinical se-
quencing annotation, has ‘C’ as nucleotide 7397, whereas
the reference genome has a ‘T’ at this position, with the
corresponding amino acids being alanine and valine, re-
spectively. Thus, an individual with a ‘C’ at this position
would have no variant detected at all in Sanger sequen-
cing data but the same individual would have a nonsy-
nonymous variant c.7397T>C_p.Val2466Ala called in
NGS data.
A second important difference is in the description of
insertions and deletions (collectively termed ‘indels’).
Annotation of indels in Sanger data is undertaken dir-
ectly in relation to the coding transcript and described
in line with the HGVS guidelines which require a variant
to be called at the most 3′ position in the coding tran-
script [4]. In NGS data, variant calls are usually reported
in a standardized Variant Call Format (VCF), which
represents indels at the most 5′ position on the forward
strand of DNA; a process called ‘left alignment’ [12].
Adherence to the VCF is not universal; for example, the
widely used mpileup command in SAMtools can report
right aligned coordinates [13, 14]. Most existing NGS
annotation tools directly annotate the supplied file re-
gardless of left or right alignment [7–9]. These tools
thus generate indel calls that are internally inconsistent
and externally incompatible because ~50 % of coding
transcripts are on the forward DNA strand and ~50 %
are on the reverse DNA strand (a small number of genes
have overlapping coding transcripts on both strands).
Most current NGS annotation tools follow the left
aligned input VCF coordinates which position an indel
at the most 3′ position if the coding transcript is on the
reverse strand (e.g., BRCA1), but at the most 5′ position
if the coding transcript is on the forward strand (e.g.,
BRCA2).
A further issue is that many indels have different pos-
sible representations. Typically, this occurs when the
indel occurs in a repetitive region. For example, if a dele-
tion of an ‘A’ is within a polyA tract such as ‘AAAAAA’,
it is not possible to definitively know which ‘A’ has been
deleted. For some indels these alternative representa-
tions have different predicted impacts on the protein
Münz et al. Genome Medicine  (2015) 7:76 Page 3 of 8and neither pre-NGS nor NGS variant annotation sys-
tems currently signpost this important scenario. For
example, an indel at the intron–exon boundary could be
classified as intronic or exonic depending on which rep-
resentation is used, with potential significant impact on
clinical interpretation (Fig. 1).
These issues became apparent to us through the Main-
streaming Cancer Genetics programme which is using
NGS to deliver large-scale, high-throughput, clinical
testing of cancer predisposition genes [15–17]. Here we
describe the tools we developed to address these chal-
lenges which we believe have broad relevance and utility
for clinical genomics.
Methods
Clinical sequencing nomenclature
We developed a standardized clinical sequencing no-
menclature (CSN) for DNA sequence variant annotation.
The aims of CSN are a) to provide a fixed, standardized
system in which every variant has a single notation, b) to
be identical for all mutation detection methods, c) to use
a logical terminology understandable to non-experts,
and d) to provide a nomenclature that allows easy visual
discrimination between the major classes of variant in
clinical genomics. The CSN follows the principles of the
HGVS nomenclature, with some minor amendments to
ensure compatibility and integration with historical clin-
ical data, whilst also allowing high-throughput automated
output from NGS platforms. The CSN is fully detailed in
Additional file 1.
Clinical Annotation of VAriants (CAVA)
To provide CSN annotation in a robust and automated
fashion, we developed a tool called CAVA (Clinical An-
notation of VAriants) which is written in Python. CAVA
is DNA ‘strand-aware’, performing coding transcript-
dependent alignment so all indels are consistently re-
ported at the most 3′ position in the coding transcript,Fig. 1 Example of an indel with alternative representations. The variant is a
would be annotated as an inframe glycine duplication in the most 3′ represen
with no impact on coding sequence if left aligned, as is typical for most NGSin line with the HGVS recommendation. CAVA also
classifies variants based on their impact on the protein
according to a simple ontology (Table 1). Within the
CAVA classification system each variant is assigned to a
single class to ensure consistency. To facilitate data
utilization and comparison with other datasets the Se-
quence Ontology (SO) classes are also given [18]. CAVA
further provides an impact flag which stratifies variants
into categories according to predicted severity of impact
on protein function, with three default classes: category
1 = ESS, FS, SG; category 2 = NSY, SS5, IF, IM, SL, EE;
and category 3 = SY, SS, INT, 5PU, 3PU.
Default variant annotations outputted by CAVA in-
clude the CSN call, variant type (substitution, insertion,
deletion or complex), HUGO Gene Nomenclature Com-
mittee (HGNC) symbol(s) of affected gene(s), Ensembl
transcript identifier(s), within-transcript location(s) (i.e.,
the exon/intron number or 5′/3′ untranslated region
(UTR)), the CAVA class, the SO term, the impact
category, and the alternative most 5′ annotation (where
appropriate). A SNP database can also be used to assign
dbSNP identifiers [2].
The user can specify the set of Ensembl transcripts
used for variant annotation instead of, or in addition to,
a default whole exome canonical transcript set provided
on installation. CAVA supports overlapping Ensembl
transcripts, i.e., a single variant call can be annotated
according to multiple transcripts. CAVA also provides
various filtering options, including removing intergenic
variant calls, i.e., calls not overlapping with any included
transcripts, or only outputting calls affecting specific
genes or genomic regions.
CAVA is lightweight and is easily added to NGS pipe-
lines as it reads variants from VCF files and outputs
either a VCF with annotations appended to the original
input or an easily parsable tab-separated text file, and
both can be written to the standard output. Processing
speed can be further increased by parallelization as‘GGG’ insertion that overlaps the 5′ boundary of BRCA2 exon 11. This
tation, as is standard for clinical annotations, but as an intronic insertion
annotation tools
Table 1 CAVA variant classification system
Class Description
SG Stop-gain (nonsense) variant caused by base substitution
ESS Any variant that alters essential splice-site base (+1, +2, −1, −2)
SS5 Any variant that alters +5 splice-site base but not an ESS base
SS Any variant that alters splice-site base within the first eight in-
tronic bases flanking exon (i.e., +8 to −8) but not an ESS or SS5
base
EE Variant that alters the first or last three bases of an exon (i.e., the
exon end), but not the frame of the coding sequence
FS Frameshifting insertion and/or deletion. It alters length and frame
of coding sequence
IM Variant that alters initiating methionine start codon
SL Variant that causes a stop-loss (i.e., the stop codon is altered)
IF Inframe insertion and/or deletion. It alters length but not frame
of coding sequence
NSY Nonsynonymous variant. It alters amino acid(s) but not coding
sequence length
SY Synonymous variant. It does not alter amino acid or coding
sequence length
INT Any variant in an intron that does not alter splice-site bases
5PU Any variant in 5′ untranslated region
3PU Any variant in 3′ untranslated region
A variant can only have one CAVA class. If a variant could potentially be
included in more than one class, the first class in the list is assigned. For
example, a frameshifting deletion that alters the start codon would be CAVA
class FS (not IM). Nonsynonymous is also known as missense. Stop-gain is also
known as nonsense
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CAVA is fully detailed in Additional file 2. CAVA is
freely available and can be downloaded from the CAVA
webpage [19].CAVA exome data annotation
The Exome Aggregation Consortium (ExAC) is a col-
laborative effort to reanalyze germline exome sequen-
cing data from 61,486 unrelated individuals contributed
by a number of disease-specific and population genetic
studies [20]. The VCF file containing 10,313,034 vari-
ants in version 0.2 was downloaded and annotated by
CAVA using a single core.
In-house exome sequencing data were available from
1000 individuals obtained from the 1958 Birth Cohort
Collection (the ICR1000 UK exome series) [21]. We used
the Illumina TruSeq Exome and sequencing was per-
formed with an Illumina HiSeq2000 generating 2 × 101
bp reads. Reads were mapped to hg19 using Stampy [22]
and duplicate reads were flagged with Picard [23]. Variants
were called with Platypus [24], generating raw VCF files.
The ICR1000 UK exome data are available from the
European Genome-phenome Archive [25]. Annotation of
the 1000 VCF files was performed by CAVA in fiveindependent jobs. Each job utilized 15 of the 16 available
cores to process files in batches of 15 in parallel with one
core per file. Four jobs processed 195 files each, and the
fifth processed the remaining 220 files.
CAVA indel annotation
To evaluate CAVA indel annotation in a typical clinical
scenario we used the raw VCF data from a single indi-
vidual from the ICR1000 series. We excluded intergenic
variants and those which only affected intronic or UTR
sequence (CAVA classes INT, 3PU, or 5PU).
CAVA clinical sequence data analysis
We used data from a clinical gene testing laboratory,
TGLclinical [26], from 25 individuals with BRCA1
mutations and 25 individuals with BRCA2 mutations.
The mutations had been identified by NGS using the
Illumina TruSight Cancer panel (TSCP) [27] and each
mutation was then verified by Sanger sequencing and
the Sanger data were used to generate the clinical re-
port. NGS analysis of TSCP used Stampy for alignment
[22] and Platypus for variant calling [24]. The default
VCF file output from Platypus was used as input for
CAVA (v.1.0), VEP (v.77), ANNOVAR (v.2014Jul14)
and SnpEff (v.4.0), which were the most recent versions
available in November 2014 when the analysis was
performed.
Results and discussion
Clinical sequencing nomenclature
The CSN is based on the HGVS guidelines to facilitate
integration with data generated by pre-NGS methods
whilst providing standardization and compatibility with
large-scale automated NGS data calling. The full details
of the CSN are provided in Additional file 1. Key details
are outlined here.
CSN provides a single variant call incorporating both
the nucleotide and amino acid change (where appropri-
ate), linked by an underscore ‘_’. Currently, most annota-
tion systems provide the nucleotide and amino acid
impact separately, either unlinked or variably linked, e.g.,
with semi-colons, commas or a space. This inconsistency
causes confusion and impedes data consolidation.
CSN standardizes the description of base substitu-
tions within genes that result in stop-gain (nonsense),
nonsyonymous (missense) and synonymous (silent) var-
iants, in a systematic format that allows easy visual
discrimination between the classes. This is very helpful
in clinical genomics as the variant class is typically not
recorded in medical records (Table 2). Historically,
HGVS has permitted different notations for stop-gain
variants, including ‘X’, ‘*’ and ‘ter’. It is clearly essential
that only one notation is used. ‘*’ is not acceptable as
this denotes a wildcard in many applications. In the
Table 2 Comparison of CSN and current nomenclature for
exonic base substitutions
CSN Current nomenclaturea
Nucleotide Amino acid
c.1040A>G_p.Gln347Arg c.1040A>G p.Gln347Arg
c.1911T>C_p.= c.1911T>C p.Gly637Gly
c.3264T>C_p.= c.3264T>C p.Pro1088Pro
c.3515C>T_p.Ser1172Leu c.3515C>T p.Ser1172Leu
c.3516G>A_p.= c.3516G>A p.Ser1172Ser
c.5682C>G_p.Tyr1894X c.5682C>G p.Tyr1894Ter
c.5855T>A_p.Leu1952X c.5855T>A p.Leu1952Ter
c.6131G>T_p.Gly2044Val c.6131G>T p.Gly2044Val
c.6675A>G_p.= c.6675A>G p.Thr2225Thr
c.7558C>T_p.Arg2520X c.7558C>T p.Arg2520Ter
c.8182G>A_p.Val2728Ile c.8182G>A p.Val2728Ile
c.9976A>T_p.Lys3326X c.9976A>T p.Lys3326Ter
CSN allows easy visual discrimination between the different classes of exonic
base substitutions with ‘=’ denoting a synonymous variant, ‘X’ denoting a
stop-gain variant and the three letter code of the new amino acid denoting
a nonsynonymous variant. CSN includes both the nucleotide and amino acid
level descriptions to give a single, unique identifier for each variant.
aThe current nomenclature given is one of several different notation systems
currently in use
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‘ter’ for three reasons. First, it allows stop-gain variants
to be readily discriminated from variants in other clas-
ses (Table 2). Second, ‘ter’ is often assumed to denote a
specific amino acid, rather than any stop codon, poten-
tially leading to misinterpretation as nonsynonymous.
Third, ‘X’ is a very widely used and well-recognized
notation for a stop codon in clinical genomics and the
scientific literature.
For nonsynonymous variants, some annotation sys-
tems use a three letter code for amino acids (e.g.,
p.Gln347Arg), whereas others use a single letter code
(e.g., p.Q347R). CSN follows the HGVS preferred rec-
ommendation of using the three letter code, which
makes it easier to recognize which amino acids are
involved: c.1040A>G_p.Gln347Arg. For synonymous
variants, some systems include the amino acid code be-
fore and after the variant position to indicate there is
no change (e.g., c.1911T>C p.Gly637Gly). However,
this makes nonsynonymous and synonymous variants
difficult to distinguish visually (Table 2). CSN follows
the HGVS recommendation of using ‘=’ to show that
the amino acid remains the same: c.1911T>C_p.=.
CSN thus provides a simple, distinctive system for ex-
onic base substitutions: ‘X’ indicates a stop-gain variant,
‘=’ indicates a synonymous variant, and a three letter
code indicates a nonsynonymous variant (Table 2).
Frameshifting indel mutations in CSN are described
using only the nucleotide change, as is typical in clinical
genomics. Many annotation systems include ahypothetical amino acid change, typically providing the
first stop-gain that would occur as a result of the frame-
shift. However, most frameshifting indels cause nonsense-
mediated RNA decay; they do not lead to a truncated pro-
tein. Therefore, this notation will be incorrect for the great
majority of indels. The CSN frameshifting indel notation
is also shorter and easier to remember and describe: e.g.,
BRCA1 c.246delT (CSN) versus BRCA1 c.246delT p.Val83-
LeufsTer5 (VEP). This is important clinically, particularly
given the prevalence of this variant class in clinical genom-
ics. CSN positions all indels at their most 3′ position in
the coding transcript, as recommended by HGVS. Posi-
tioning in relation to the forward strand of DNA, as per-
formed by most NGS annotation tools, is unacceptable as
it results in annotation inconsistency as described above.CAVA
To provide CSN annotation in a fast, robust, automated
fashion, we developed a tool called CAVA (Clinical
Annotation of VAriants). CAVA classifies variants based
on a simple, explicit, logical ontology focused on clinical
requirements, which avoids historical jargon, such as ‘non-
sense’ for a stop-gain mutation. The ontology deliberately
focuses on the likely clinical impact of variants, e.g., expli-
citly recognizing any variants that alter the first and last
codons of an exon as these often result in splicing defects
(Table 1). Additionally, in the CAVA classification system
each variant has only one class, to ensure consistency in
variant classification. However, the SO classes are also pro-
vided to facilitate analyses and interchange with other data-
sets [18].
CAVA uses Ensembl transcripts to ensure variants
called against the reference human genome are anno-
tated correctly. A default database is included but there
is also flexibility to use a bespoke, user-generated tran-
script database. Importantly, CAVA adjusts for the
DNA strand of the coding transcript, so that indels are
always called at the most 3′ position in the coding
transcript, in line with HGVS and CSN. Furthermore,
CAVA flags any variant with potential alternative repre-
sentations, outputting the alternative annotations as
well. This is extremely important clinically as it ensures
that, where appropriate, the most deleterious potential
consequence of a variant can be investigated (e.g.,
Fig. 1). Highlighting variants with alternative possible
annotations also facilitates comparisons with variant
sets annotated with other tools. Examples of the default
CAVA outputs are shown in Table 3.
In addition to providing consistent clinical annotations,
CAVA is freely available and designed to be lightweight,
flexible and easily appended to any NGS pipeline to pro-
vide high utility for clinical and research applications. Full
details of CAVA are provided in Additional file 2.
Table 3 Example default output of CAVA v.1.0
Chr Pos Ref Alt Qual Filter Type ENST Gene TRINFO Loc
1 12009955 C T 200 PASS Substitution ENST00000196061 PLOD1 +/40.8 kb/19/2.9 kb Ex3
1 12919891 G T 200 PASS Substitution ENST00000240189 PRAMEF2 +/4.8 kb/4/1.6 kb Ex3
1 14106394 A ACTC 200 PASS Insertion ENST00000235372 PRDM2 +/120.2 kb/10/7.9 kb Ex8
1 15789297 A C 200 PASS Substitution ENST00000359621 CELA2A +/15.4 kb/8/0.9 kb Ex4
1 15812432 A G 200 PASS Substitution ENST00000375910 CELA2B +/15.3 kb/8/0.9 kb Ex6
1 16727305 G GCTT 200 PASS Insertion ENST00000335496 SPATA21 -/38.8 kb/13/2.0 kb Ex11
1 22310824 T C 200 PASS Substitution ENST00000337107 CELA3B +/12.3 kb/8/0.9 kb Ex6
1 31905889 A ACAG 200 PASS Insertion ENST00000373710 SERINC2 +/25.1 kb/11/2.1 kb Ex10
1 36937059 A G 200 PASS Substitution ENST00000373103 CSF3R -/17.2 kb/17/3.5 kb Ex10
1 38023316 C T 200 PASS Substitution ENST00000296218 DNALI1 +/9.9 kb/6/2.6 kb Ex2
1 43771016 TA T 200 PASS Deletion ENST00000372476 TIE1 +/22.1 kb/23/3.9 kb In3/4
1 54605319 G GC 200 PASS Insertion ENST00000371330 CDCP2 -/14.8 kb/4/2.7 kb Ex4
1 55251689 T C 200 PASS Substitution ENST00000371276 TTC22 -/21.6 kb/7/3.3 kb Ex5
1 55603581 T TA 200 PASS Insertion ENST00000294383 USP24 -/149.0 kb/68/10.8 kb In26/27
1 60503762 T C 200 PASS Substitution ENST00000371201 C1orf87 -/83.4 kb/12/2.0 kb Ex6
1 62232031 C T 200 PASS Substitution ENST00000371158 INADL +/421.4 kb/43/8.5 kb Ex4
1 67155862 TCTC T 200 PASS Deletion ENST00000371037 SGIP1 +/210.8 kb/25/4.6 kb In16/17
Table 3 Example default output of CAVA v.1.0 (Continued)
CSN Class SO Impact Alt ann Alt class Alt SO
c.294C>T_p.= SY Synonymous_variant 3 . . .
c.631G>T_p.Glu211X SG Stop_gained 1 . . .
c.2107_2109dupCCT_p.Pro703dup IF Inframe_insertion 2 c.2104_2105insCTC_p.Pro703dup . .
c.297A>C_p.= SY Synonymous_variant 3 . . .
c.530A>G_p.Gln177Arg NSY Missense_variant 2 . . .
c.1081_1083dupAAG_p.Lys361dup IF Inframe_insertion 2 c.1078_1079insAGA_p.Lys361dup . .
c.642 T>C_p.= EE Aplice_region_variant|synonymous_variant 2 . . .
c.1129_1131dupCAG_p.Gln377dup IF Inframe_insertion 2 c.1116_1117insCAG_p.Gln377dup . .
c.1260 T>C_p.= SY Synonymous_variant 3 . . .
c.260C>T_p.Ala87Val NSY Missense_variant 2 . . .
c.484 + 5delA SS5 Splice_donor_5th_base_variant 2 c.484 + 3delA . .
c.1223_1224insG FS Frameshift_variant 1 . . .
c.987A>G_p.= SY Synonymous_variant 3 . . .
c.2929-5dupT SS Intron_variant|splice_region_variant 3 c.2929-9_2929-8insT INT intron_variant
c.765A>G_p.= SY Synonymous_variant 3 . . .
c.270C>T_p.= SY Synonymous_variant 3 . . .
c.1444-8_1444-6delCCT SS Intron_variant|splice_region_variant 3 c.1444-10_1444-8delCTC . .
Chr chromosome, Pos position, Ref reference alllele, Alt alternative allele, Qual quality score, TRINFO transcript information, Loc location in transcript, Alt ann alternative annotation, Alt class alternative class, Alt SO
alternative SO term
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To evaluate performance in annotating large variant
datasets we used CAVA to annotate the ExAC data.
Annotation of 10,313,034 variants took 13.44 hours, i.e.,
at a rate of 14,234 variants/minute. Faster annotation
would be easily attainable with parallelization. This
annotation was also of practical utility because the
ExAC data in version 0.2 provides only the amino acid
change for exonic base substitutions, which impedes
clinical utilization and comparison with other data, par-
ticularly since the degeneracy of the genetic code allows
different mutations at the nucleotide level to result in
the same mutation at the amino acid level.
To evaluate CAVA performance in real-time whole
exome annotation we analyzed the ICR1000 UK exome
series using parallelized annotation in batches of 15
exomes. The average file had 170,900 variants (range
108,400–225,000), and the 1000 exomes were anno-
tated in ~6.5 hours. We used the data from one individ-
ual to evaluate CAVA indel annotation in a typical
clinical scenario. This individual had 731 different
indels, which were distributed equally amongst genes
with coding transcripts on the forward and reverse
DNA strands (Additional file 3); 92 % (675/731) of
indels had an alternative representation and would thus
be represented differently in left aligned and right
aligned data. Annotation tools that do not incorporate
the strand of the coding transcript would thus lead to
calls discrepant with clinical annotation for 339 indels
(those in genes transcribed from the forward DNA
strand); 46 % of all indels in this individual. Further-
more, 370 indels had an alternative representation that
was also of a different class (Additional file 3). This
includes 27 indels for which only one representation
was predicted to cause premature protein truncation
(either FS or ESS). The functional and clinical implica-
tions of truncating and non-truncating variants are
potentially very different and it is thus essential in clin-
ical genomics that such variants are highlighted.
CAVA clinical annotation
To evaluate and compare CAVA and standard NGS
annotation tools for indels in the clinical setting we used
data from a BRCA1 and BRCA2 clinical testing laboratory,
in which testing is performed by NGS panel analysis with
pathogenic indel mutations confirmed by Sanger sequen-
cing. We evaluated 25 BRCA1 and 25 BRCA2 indels (Add-
itional file 4). CAVA provided annotations consistent with
the clinical report for all 50 mutations. Additionally, CAVA
flagged that alternative annotations were possible for 34
mutations, though none altered the class (i.e., all possible
representations result in a frameshift). By contrast, only 8
out of 25 (32 %) of the BRCA2 indels were correctly clinic-
ally annotated by other tools (Additional file 4).Conclusions
We have highlighted in this paper some of the rudimen-
tary problems in variant annotation that are hindering
the large-scale implementation of genomic medicine
that NGS is poised to deliver. A fundamental problem
is the absence of consistent annotation of variants in
the clinic. We here introduce the CSN, a nomenclature
for clinical sequence data which we believe can serve as
the foundation of an integrative, cross-platform annota-
tion system optimized for technological, informatic and
clinical requirements. There remain several areas re-
quiring standardization, e.g., a defined, consensus set of
gene transcripts against which to perform clinical anno-
tation must be decided. Expansion of CSN to provide
standardization of annotation of additional variant clas-
ses, such as larger exonic deletions and duplications,
will also be required. Ongoing CSN iteration, performed
by an appropriately representative group, and with all
modifications explicitly detailed and versioned, will thus
be essential.
We also show the profound impact that the stranded-
ness of transcripts can have on the annotation and inter-
pretation of indels. It is essential that all variant
annotation tools recognize and address this issue. We
have developed CAVA, a freely available, lightweight an-
notation tool that can be readily appended to NGS pipe-
lines and which incorporates the transcript strand to
provide consistent, clinically appropriate indel calls.
Equally importantly, CAVA highlights indels that have
possible alternative annotations so that fully informed
clinical interpretation can be performed.
We have implemented CSN using CAVA in a clinical
gene testing lab performing cancer predisposition gene
panel testing, allowing robust, high-throughput gene
testing, adhering to clinical testing standards, to be de-
livered. The problems we highlight and the solutions we
have developed are generic and therefore should have
broad relevance and utility in genomic medicine.
Additional files
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